CD8A and neoplasm: In this context, the therapeutic efficacy is highly dependent on a sufficient and proper presentation of cancer antigens on major histocompatibility complexes (MHC)-I and -II by antigen presenting cells (APCs) to elicit activation and effector function of tumor-reactive CD8+ and CD4+ T lymphocytes [6, 7].